GlassScriptPhysician profile
Terrence Jones
NPI 1295390516
$1,277.44
in general payments reported to CMS, 2019-2025
20 companies · $320 in 2025
The $320 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $81.04 · 2024: $877 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252 · Education: $25.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.72 |
| Education | $25.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $421.65 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $142.48 | 2024 | Ultomiris |
| Beigene USA, INC. | $140.63 | 2024-2025 | Brukinsa |
| Glaxosmithkline, LLC. | $81.04 | 2023 | |
| Merck Sharp & Dohme LLC | $74.80 | 2024 | Keytruda, Reblozyl, Welireg |
| Sobi, INC | $51.08 | 2024 | |
| Novartis Pharmaceuticals Corporation | $48.84 | 2024 | |
| Adaptive Biotechnologies Corporation | $42.34 | 2024 | Clonoseq |
| Incyte Corporation | $38.22 | 2025 | Jakafi, Niktimvo |
| Janssen Biotech, INC. | $36.67 | 2024-2025 | Carvykti, Tecvayli, Talvey |
| Janssen Pharmaceuticals, INC | $25.72 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2024 | Ninlaro |
| Lilly USA, LLC | $22.06 | 2024 | Jaypirca |
| Beone Medicines USA, INC. | $21.73 | 2025 | Brukinsa |
| Pacira Pharmaceuticals Incorporated | $21.05 | 2024 | Exparel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $18.18 | 2024 | Poteligeo |
| Genentech USA, INC. | $17.33 | 2024 | Venclexta |
| Servier Pharmaceuticals LLC | $16.86 | 2024 | |
| Exelixis INC. | $16.63 | 2024 | Cabometyx |
| Abbvie INC. | $15.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.